Pramlintide combination therapyAlternative Names: pramlintide + phentermine; pramlintide + PYY3-36; pramlintide + sibutramine; pramlintide/phentermine; pramlintide/PYY3-36; pramlintide/sibutramine
Latest Information Update: 05 Jan 2016
At a glance
- Originator Amylin Pharmaceuticals
- Class Cyclobutanes; Macromolecular substances; Neuropeptides
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Islet amyloid polypeptide stimulants; Leptin receptor agonists; Neuropeptide Y2 receptor agonists; Neurotransmitter stimulants; Serotonin uptake inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity